A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer (Q27851729)

Wan-Teck Lim

53

0 references

Yasushi Yatabe

Yasushi Yatabe

49

0 references

Markus M Nöthen

Markus M Nöthen

42

0 references

Anbupalam Thalamuthu

18

Anbupalam Thalamuthu

0 references

Atif Shahab

44

Atif Shahab

0 references

author name string

King Pan Ng

1

0 references

Charles T H Chuah

3

0 references

Wen Chun Juan

4

0 references

Tun Kiat Ko

5

0 references

Audrey S M Teo

6

0 references

Pramila N Ariyaratne

7

0 references

Naoto Takahashi

8

0 references

Kenichi Sawada

9

0 references

Yao Fei

10

0 references

Sheila Soh

11

0 references

Wah Heng Lee

12

0 references

John W J Huang

13

0 references

John C Allen

14

0 references

Xing Yi Woo

15

0 references

Niranjan Nagarajan

16

0 references

Vikrant Kumar

17

0 references

Wan Ting Poh

19

0 references

Ai Leen Ang

20

0 references

Hae Tha Mya

21

0 references

Gee Fung How

22

0 references

Li Yi Yang

23

0 references

Liang Piu Koh

24

0 references

Balram Chowbay

25

0 references

Chia-Tien Chang

26

0 references

Veera S Nadarajan

27

0 references

Wee Joo Chng

28

0 references

Hein Than

29

0 references

Lay Cheng Lim

30

0 references

Yeow Tee Goh

31

0 references

Shenli Zhang

32

0 references

Dianne Poh

33

0 references

Patrick Tan

34

0 references

Ju-Ee Seet

35

0 references

Mei-Kim Ang

36

0 references

Noan-Minh Chau

37

0 references

Quan-Sing Ng

38

0 references

Daniel S W Tan

39

0 references

Manabu Soda

40

0 references

Kazutoshi Isobe

41

0 references

Tien Y Wong

43

0 references

Xiaoan Ruan

45

0 references

Valère Cacheux-Rataboul

46

0 references

Wing-Kin Sung

47

0 references

Eng Huat Tan

48

0 references

Hiroyuki Mano

50

0 references

Ross A Soo

51

0 references

Tan Min Chin

52

0 references

Yijun Ruan

54

0 references

S Tiong Ong

Factors underlying sensitivity of cancers to small-molecule kinase inhibitors

55

0 references

language of work or name

English

0 references

publication date

18 March 2012

0 references

1 reference

18

0 references

page(s)

521-8

0 references

issue

4

0 references

cites work

1 reference

Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics

21 April 2017

1 reference

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations

21 April 2017

1 reference

Comprehensive long-span paired-end-tag mapping reveals characteristic patterns of structural variations in epithelial cancer genomes

21 April 2017

1 reference

Exploring prokaryotic diversity in the genomic era

21 April 2017

1 reference

BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis

21 April 2017

1 reference

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 April 2017

1 reference

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 April 2017

1 reference

Characterizing tyrosine phosphorylation signaling in lung cancer using SH2 profiling

21 April 2017

1 reference

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 April 2017

1 reference

A second generation human haplotype map of over 3.1 million SNPs

21 April 2017

1 reference

Highly efficient endogenous human gene correction using designed zinc-finger nucleases

21 April 2017

1 reference

The BCL-2 protein family: opposing activities that mediate cell death

21 April 2017

1 reference

Erlotinib in previously treated non-small-cell lung cancer

21 April 2017

1 reference

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 April 2017

1 reference

Listening to silence and understanding nonsense: exonic mutations that affect splicing

21 April 2017

1 reference

American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.

21 April 2017

1 reference

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

21 January 2018

1 reference

Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.

21 January 2018

1 reference

Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds.

21 January 2018

1 reference

Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors

21 January 2018

1 reference

Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas

21 January 2018

1 reference

Next-generation DNA sequencing of paired-end tags (PET) for transcriptome and genome analyses

21 January 2018

1 reference

Nomenclature of dynein light chain-linked BH3-only protein Bim isoforms.

21 January 2018

1 reference

An intronic sequence element mediates both activation and repression of rat fibroblast growth factor receptor 2 pre-mRNA splicing

21 January 2018

1 reference

BH3-Only proteins-essential initiators of apoptotic cell death

21 January 2018

1 reference

Establishment of a Ph 1 chromosome‐positive cell line from chronic myelogenous leukemia in blast crisis

21 January 2018

1 reference

Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis

21 January 2018

1 reference

Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics

21 January 2018

1 reference

Resistance to imatinib in chronic myelogenous leukemia: mechanisms and clinical implications

21 January 2018

1 reference

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

21 January 2018

1 reference

A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha

21 January 2018

1 reference

Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response

21 January 2018

1 reference

EGFR exon 20 insertion mutation in Japanese lung cancer.

21 January 2018

1 reference

Role for the proapoptotic factor BIM in mediating imatinib-induced apoptosis in a c-KIT-dependent gastrointestinal stromal tumor cell line

21 January 2018

1 reference

Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells.

21 January 2018

1 reference

Chronic myeloid leukemia in Asia

21 January 2018

1 reference

BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors.

21 January 2018

1 reference

Are splicing mutations the most frequent cause of hereditary disease?

21 January 2018

1 reference

Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.

21 January 2018

1 reference

FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR.

21 January 2018

1 reference

De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer

21 January 2018

1 reference

Bim is a suppressor of Myc-induced mouse B cell leukemia

21 January 2018

1 reference

Rationale and methodology for a population-based study of eye diseases in Malay people: The Singapore Malay eye study (SiMES).

21 January 2018

1 reference

Methodology of the Singapore Indian Chinese Cohort (SICC) eye study: quantifying ethnic variations in the epidemiology of eye diseases in Asians

21 January 2018

1 reference

Integrated genotype calling and association analysis of SNPs, common copy number polymorphisms and rare CNVs

21 January 2018

1 reference

Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin

21 January 2018

1 reference

12 December 2020

Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.

1 reference

12 December 2020

New insights in biology and current therapeutic options for patients with chronic myelogenous leukemia.

1 reference

12 December 2020

Finding signals that regulate alternative splicing in the post-genomic era

1 reference

12 December 2020

Genomics and drug response

1 reference

12 December 2020

The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells

1 reference

12 December 2020

Identification and characterization of Bimgamma, a novel proapoptotic BH3-only splice variant of Bim

1 reference

12 December 2020

Identifiers

DOI

10.1038/NM.2713

1 reference

Consolidated OpenCitations Corpus – April 2017

Dimensions Publication ID

578445

1028536763

0 references

578445

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference